Welcome to the international HTA database

Showing [21797 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2008	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Interferons and natalizumab for multiple sclerosis]
2015	Haute Autorite de sante (HAS)	[Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection]
2010	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Interferon-gamma release assays (IGRAs) for diagnosis of latent tuberculosis infection and active tuberculosis]
2007	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Interdisciplinary follow-up with actors in primary health care]
2007	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Intensive polypharmacological treatment of type 2-diabetes in daily clinical practice - a health technology assessment]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intensity-modulated radiotherapy for prostate cancer]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intensity-modulated radiation therapy for breast cancer]
2005	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Intensity modulated radiotherapy]
2012	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intensity modulated radiotherapy (IMRT) for prostate cancer]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intensity modulated radiation therapy for three dimensional breast cancer]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intense-pulse-light therapy treatment for dry eye syndrome]
2010	Basque Office for Health Technology Assessment (OSTEBA)	[Integrated intra and extra-hospital approach to conduct disorders in adolescence]
2015	Institut national d'excellence en sante et en services sociaux (INESSS)	[Insulin pumps in the treatment of type 1 diabetes]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Insulin infusion pumps for diabetic patients]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2012	Institute for Clinical Effectiveness and Health Policy (IECS)	[Insulin Detemir therapy in pediatric and pregnant population]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin degludec/liraglutide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin degludec/liraglutide (Addendum to Commission A15-15)]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin degludec/liraglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin degludec (diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin degludec (addendum to commission A15-10)]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin degludec - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015	The Swedish Council on Health Technology Assessment (SBU)	[Instruments for suicide risk assessment]
2017	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Inotuzumab ozogamicin (acute lymphocytic leukaemia) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Inotersen (hereditary transthyretin amyloidosis with polyneuropathy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[Initial staging of oesophageal cancer: systematic review of the performance of diagnostic methods]
2009	Institute for Clinical Effectiveness and Health Policy (IECS)	[Inhaled tobramycin for cystic fibrosis]
2006	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Inhaled insulin (Exubera) in diabetes mellitus - rapid report]
2013	Institute for Clinical Effectiveness and Health Policy (IECS)	[Inhalation tobramycin for the management of cystic fibrosis]
2007	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Inguinal hernia: clinical practice guideline]
2012	The Netherlands Organisation for Health Research and Development (ZonMw)	[Inguinal hernia management: operation or observation? A randomised controlled multicenter trial]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Infrared meibography for meibomian gland disease]
2011	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Informative value of Patient-Reported Outcomes (PRO) in Health Technology Assessment (HTA)]
2012	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Information, consent and medical counselling on ultrasound screening in pregnancy]
2007	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Information to users on cancer screening in women: assessment of current situation and establishment of evidence-based information standards. 1. Information to users on breast cancer screening]
2010	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Information to users on cancer screening in women: assessment of current situation and establishment of evidence-based information standards 2. Information to users on cervical cancer screening]
2009	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Information to parents about neonatal screening for inborn errors of metabolism: assessment of current situation and establishment evidence-based information standards]
2010	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Information resources: developing user guides]
2006	Basque Office for Health Technology Assessment (OSTEBA)	[Information required for analyzing the impact of the early breast cancer detection programme]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Information for health insurance fund members on ultrasound screening for abdominal aortic aneurysms: addendum to commission S13-04]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Information for health insurance fund members on prenatal testing]
2015	Institut national d'excellence en sante et en services sociaux (INESSS)	[Information brief concerning palliative care day centres]
2009	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Information and communications technologies in mental health (Telepsychiatry)]
2009	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Information and communications technologies in CHF management programmes. Organizational challenges and evidence status]
2008	Committee for New Health Technology Assessment (CNHTA)	[Influenza virus A & B, RT-nested PCR]
2021	Health Council of the Netherlands Gezondheidsraad (GR)	[Influenza vaccination: review of indications]
2000	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Influenza vaccination of the elderly (funded by DIHTA)]
2022	Canary Health Service	[Influenza vaccination in children 6 to 59 months of age]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Influence of an existing health care plan aimed at managing ST-elevation myocardial infarction on the waiting time until re-perfusion, and types of re-perfusion. Pilot study]
2007	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Infliximab in patients with arthritis psoriatic: systematic review of the clinical and economic literature]
2004	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Infliximab (REMICADE) in patients with rheumatoid arthritis; systematic review of the clinical and economic literature]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) - Benefit assessment according to § 35a SGB V]
2010	The Netherlands Organisation for Health Research and Development (ZonMw)	[Induction of labour versus expectant management in women with preterm premature rupture of membranes between 34 and 37 weeks (PPROMEXIL-study)]
2012	The Regional Health Technology Assessment Centre (HTA-centrum)	[Induction of labour at 41 completed until 42 completed gestational weeks, update of mini-HTA VGR 2007]
2019	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Induction immunosuppressive therapy in patients undergoing heart transplantation]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Induced sputum in severe asthma patients]
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Individualised multidisciplinary care programme in frail patients (PAMI)]
2011	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Individual health services]
2010	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Indirect comparisons of therapeutic interventions]
2013	National Evidence-based Healthcare Collaborating Agency (NECA)	[Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator]
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Indications, utility and use of ultrasound in primary care]
2011	Institut national d'excellence en sante et en services sociaux (INESSS)	[Indications for positron emission tomography (pet): a brief update]
2008	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[Indications for hyperbaric oxygen therapy: update]
2012	Basque Office for Health Technology Assessment (OSTEBA)	[Indications and recommendations for the use of PET-CT in the planning of radiation oncology treatment. Systematic review]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Indicaterol/glycopyrronium - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2024	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Indicated prevention of suicide in children and adolescents]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69]
2010	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Increase of physical activity in essential hypertension - Rapid report]
2023	Health Sciences Institute in Aragon (IACS)	[Incorporation of expanded genetic analysis to assist the assessment of venous thromboembolism risks and recurrent spontaneous miscarriages]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Inclusion of new health technologies into Spanish hospitals]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Inclisiran (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Incidence of errors in intensive care: effects of increased awareness and of improved communication by the introduction of explicit daily goals]
2006	Basque Office for Health Technology Assessment (OSTEBA)	[Incidence of diabetic retinopathy based on a screening programme using a non-mydriatic retinal camera on diabetic patients in the Autonomous Community of the Basque Country]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism - Addendum to commission H22-04]
2009	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[In vitro fertilization: comparative profile of European and Oceania countries]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Improving the efficiency and quality of follow-up after curative treatment for breast cancer]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Improving the early diagnosis of myocardial infarction in primary care: the added value of a rapid assay to detect heart-type FABP, a novel marker of cardiac injury]
2009	Basque Office for Health Technology Assessment (OSTEBA)	[Improving the care of elderly patients with chronic pathologies]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Improving lifestyle adherence in patients with high risk for cardiovascular diseases in general practice. Costs and effects of patient involvement in cardiovascular risk management]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementing a routine outcome monitoring system to study the effectiveness of long-term psychoanalytic treatment and therapeutic decision making in four cohorts of personality disordered and/ or recurrent or chronic depressive patients]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of the WIP guideline 'Prevention of infections due to urethral bladder catheterization']
2010	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of structural feedback by means of perinatal audit to caregivers in cases of perinatal mortality in the northern part of the Netherlands (IMPACT)]
2010	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of selective karyotyping in couples with recurrent miscarriage]
2012	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of screening and treatment of high-risk fracture patients by an osteoporosis nurse-practitioner]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Implementation of quality indicators to assess the high risk of colorectal cancer clinic]
2012	The Swedish Council on Health Technology Assessment (SBU)	[Implementation of psychiatric guidelines and evidence-based knowledge in the primary care sector]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of outpatient schema focused therapy for borderline personality disorder in three settings: general community mental health centers, forensic centers and addiction treatment centers]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of intensive insulin therapy (IIT) in critically ill patients, targeting at normoglycemia while preventing hypoglycemia]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implementation of guidelines - obstructive and beneficial factors]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of evidence-based guidelines for appropriate use of ultrasonography in diagnostic breast imaging: the MAMMOED-2 study]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of an evidence based smoking cessation strategy (SMOCC) for patients with COPD in primary care]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[IMPlementation of a prediction rule in Anesthesia practice to improve Cost-effectiveness of Treatment of postoperative nausea and vomiting: the IMPACT trial]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of a new cost-effective treatment (HIT) for patients with therapy refractory auditory hallucinations]
2012	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of a multiple intervention aimed at optimising prescription of antibiotics for respiratory tract infections, embedded within the new practice accreditation of the Dutch College of General Practitioners; a randomized controlled trial]